Related Experiment Video

Updated: Aug 24, 2026

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

Sphingolipid metabolism enzymes as targets for anticancer therapy

J W Kok1, H Sietsma

  • 1Department of Cell Biology, Section Membrane Cell Biology, Groningen University Institute for Drug Exploration, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands. j.w.kok@med.rug.nl

Current Drug Targets
|May 12, 2004
PubMed

Insights

Targeting sphingolipid metabolism, particularly glucosylceramide synthase, offers a novel strategy to overcome cancer multidrug resistance by enhancing apoptotic cell death. This approach aims to restore sensitivity to anti-cancer agents.

Area of Science:

  • Biochemistry
  • Cell Biology
  • Oncology

Background:

  • Anti-cancer treatments typically induce apoptotic cell death.
  • Multidrug resistance (MDR) in tumor cells hinders treatment efficacy, often by reducing apoptosis.
  • Sphingolipid metabolism, particularly ceramide, plays a key role in apoptosis.

Purpose of the Study:

  • To explore the role of sphingolipid metabolism in MDR.
  • To identify potential therapeutic targets within sphingolipid pathways to overcome MDR.
  • To review how modulating sphingolipid metabolism can enhance anti-cancer therapy.

Main Methods:

  • Review of current literature on sphingolipid metabolism and MDR.
  • Analysis of changes in sphingolipid composition in multidrug-resistant cells.
  • Identification of key enzymes in sphingolipid metabolism as potential therapeutic targets.

Main Results:

  • Increased glucosylceramide levels, due to elevated glucosylceramide synthase activity, are a hallmark of MDR.
  • Altered sphingolipid metabolism is a common feature of multidrug-resistant cancer cells.
  • Targeting glucosylceramide synthase can potentially restore apoptosis and overcome MDR.

Conclusions:

  • Modulating sphingolipid metabolism presents a promising strategy to combat cancer multidrug resistance.
  • Glucosylceramide synthase is a key target for restoring sensitivity to chemotherapeutics.
  • Further investigation into sphingolipid metabolic pathways may reveal additional targets for anti-cancer therapy.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...